These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 24064467)

  • 1. Evidence of pre-synaptic dopaminergic deficit in a patient with a novel progranulin mutation presenting with atypical parkinsonism.
    Carecchio M; Galimberti D; Fenoglio C; Serpente M; Scarpini E; Comi C; Terazzi E; Cantello R
    J Alzheimers Dis; 2014; 38(4):747-52. PubMed ID: 24064467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease.
    Carecchio M; Fenoglio C; De Riz M; Guidi I; Comi C; Cortini F; Venturelli E; Restelli I; Cantoni C; Bresolin N; Monaco F; Scarpini E; Galimberti D
    J Neurol Sci; 2009 Dec; 287(1-2):291-3. PubMed ID: 19683260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer's disease: detection of GRN mutations in a Spanish cohort.
    Antonell A; Gil S; Sánchez-Valle R; Balasa M; Bosch B; Prat MC; Chiollaz AC; Fernández M; Yagüe J; Molinuevo JL; Lladó A
    J Alzheimers Dis; 2012; 31(3):581-91. PubMed ID: 22647257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extensive white matter involvement in patients with frontotemporal lobar degeneration: think progranulin.
    Caroppo P; Le Ber I; Camuzat A; Clot F; Naccache L; Lamari F; De Septenville A; Bertrand A; Belliard S; Hannequin D; Colliot O; Brice A
    JAMA Neurol; 2014 Dec; 71(12):1562-6. PubMed ID: 25317628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study.
    Le Ber I; Camuzat A; Hannequin D; Pasquier F; Guedj E; Rovelet-Lecrux A; Hahn-Barma V; van der Zee J; Clot F; Bakchine S; Puel M; Ghanim M; Lacomblez L; Mikol J; Deramecourt V; Lejeune P; de la Sayette V; Belliard S; Vercelletto M; Meyrignac C; Van Broeckhoven C; Lambert JC; Verpillat P; Campion D; Habert MO; Dubois B; Brice A;
    Brain; 2008 Mar; 131(Pt 3):732-46. PubMed ID: 18245784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred.
    Pietroboni AM; Fumagalli GG; Ghezzi L; Fenoglio C; Cortini F; Serpente M; Cantoni C; Rotondo E; Corti P; Carecchio M; Bassi M; Bresolin N; Galbiati D; Galimberti D; Scarpini E
    J Alzheimers Dis; 2011; 24(2):253-9. PubMed ID: 21258152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel GRN g.1159_1160delTG mutation is associated with behavioral variant frontotemporal dementia.
    Calvi A; Cioffi SM; Caffarra P; Fenoglio C; Serpente M; Pietroboni AM; Arighi A; Ghezzi L; Gardini S; Scarpini E; Galimberti D
    J Alzheimers Dis; 2015; 44(1):277-82. PubMed ID: 25261445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of the pre and post-synaptic dopaminergic system by DaTSCAN/IBZM SPECT in the differential diagnosis of parkinsonism in 75 patients].
    Vaamonde J; Ibáñez R; García AM; Poblete V
    Neurologia; 2004; 19(6):292-300. PubMed ID: 15199417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [DaT-SCAN SPECT in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease].
    Vaamonde-Gamo J; Flores-Barragán JM; Ibáñez R; Gudín M; Hernández A
    Rev Neurol; 2005 Sep 1-15; 41(5):276-9. PubMed ID: 16138284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
    Lim TT; Ahmed A; Itin I; Gostkowski M; Rudolph J; Cooper S; Fernandez HH
    Int J Neurosci; 2013 Mar; 123(3):170-4. PubMed ID: 23078283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging dopamine transporters in Parkinson's disease.
    Brooks DJ
    Biomark Med; 2010 Oct; 4(5):651-60. PubMed ID: 20945978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine transporter binding in chronic manganese intoxication.
    Huang CC; Weng YH; Lu CS; Chu NS; Yen TC
    J Neurol; 2003 Nov; 250(11):1335-9. PubMed ID: 14648150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GRN Thr272fs clinical heterogeneity: a case with atypical late onset presenting with a dementia with Lewy bodies phenotype.
    Arosio B; Abbate C; Galimberti D; Rossi PD; Inglese S; Fenoglio C; Ridolfi E; Gussago C; Casati M; Tedone E; Ferri E; Serpente M; Scarpini E; Mari D
    J Alzheimers Dis; 2013; 35(4):669-74. PubMed ID: 23478307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic variability of familial and sporadic Progranulin p.Gln257Profs*27 mutation.
    Pires C; Coelho M; Valadas A; Barroso C; Pimentel J; Martins M; Duyckaerts C; de Mendonça A; Verdelho A; Miltenberger-Miltenyi G
    J Alzheimers Dis; 2013; 37(2):335-42. PubMed ID: 23813535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and MRI correlates of disease progression in a case of nonfluent/agrammatic variant of primary progressive aphasia due to progranulin (GRN) Cys157LysfsX97 mutation.
    Caso F; Agosta F; Magnani G; Galantucci S; Spinelli EG; Galimberti D; Falini A; Comi G; Filippi M
    J Neurol Sci; 2014 Jul; 342(1-2):167-72. PubMed ID: 24814951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretory leukocyte protease inhibitor protein regulates the penetrance of frontotemporal lobar degeneration in progranulin mutation carriers.
    Ghidoni R; Flocco R; Paterlini A; Glionna M; Caruana L; Tonoli E; Binetti G; Benussi L
    J Alzheimers Dis; 2014; 38(3):533-9. PubMed ID: 24018267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide.
    Stamelou M; Quinn NP; Bhatia KP
    Mov Disord; 2013 Aug; 28(9):1184-99. PubMed ID: 23720239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early neuropsychological characteristics of progranulin mutation carriers.
    Hallam BJ; Jacova C; Hsiung GY; Wittenberg D; Sengdy P; Bouchard-Kerr P; Slack P; Rademakers R; Baker M; Chow TW; Levine B; Feldman HH; Mackenzie IR
    J Int Neuropsychol Soc; 2014 Aug; 20(7):694-703. PubMed ID: 24993774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia.
    van Swieten JC; Heutink P
    Lancet Neurol; 2008 Oct; 7(10):965-74. PubMed ID: 18771956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid biomarkers in Progranulin mutations carriers.
    Carecchio M; Fenoglio C; Cortini F; Comi C; Benussi L; Ghidoni R; Borroni B; De Riz M; Serpente M; Cantoni C; Franceschi M; Albertini V; Monaco F; Rainero I; Binetti G; Padovani A; Bresolin N; Scarpini E; Galimberti D
    J Alzheimers Dis; 2011; 27(4):781-90. PubMed ID: 21891865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.